Status In progress
Process STA
ID number 893

Provisional Schedule

Expected publication 27 September 2017
Appeal 03 November 2017

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors Pfizer (inotuzumab ozogamicin)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
Professional groups Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated guideline groups None
Associated public health groups None
Comparator companies Accord Healthcare (cytarabine, filgrastim, fludarabine)(Confidentiality agreement not signed not participating)
  Allergan (fludarabine) (Confidentiality agreement not signed not participating)
  Amgen (filgrastim) (Confidentiality agreement not signed not participating)
  Bristol-Myers Squibb (dasatinib) (Confidentiality agreement not signed not participating)
  Chugai Pharma UK (lenograstim) (Confidentiality agreement not signed not participating)
  Hospira UK (cytarabine, filgrastim, fludarabine)(Confidentiality agreement not signed not participating)
  Novartis (imatinib) (Confidentiality agreement not signed not participating)
  Sandoz (filgrastim, fludarabine) (Confidentiality agreement not signed not participating)
  Sanofi (clofarabine, fludarabine) (Confidentiality agreement not signed not participating)
  Teva Pharma (lipegfilgrastim) (Confidentiality agreement not signed not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland

Timeline

Key events during the development of the guidance:

Date Update
18 August 2017 - 04 September 2017 Final appraisal determination
12 July 2017 Committee meeting: 2
06 June 2017 - 04 July 2017 Appraisal consultation
16 May 2017 Committee meeting: 1
09 December 2016 Invitation to participate
21 November 2016 Draft scope documents
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance